Mavenclad is a drug currently under review by the Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis. Mavenclad is also referred to by its drug name, Cladribine. Although Mavenclad has not yet received FDA approval, some people in the U.S. with multiple sclerosis are already receiving Mavenclad by participating in clinical trials.
Mavenclad is an immunomodulator, or in other words, a drug that modulates the immune system. Mavenclad is believed to work by reducing the number of B and T lymphocytes, immune cells that contribute to autoimmune attacks in MS.
How do I take it?read more
In clinical studies, Mavenclad is taken as a tablet in two short courses over two years. Mavenclad is taken for five days in a row the first month and again five days in a row the second month. After 12 months, the two short courses of Mavenclad are repeated.
Clinical studies have reported common side effects including rash, hair loss, herpes infection (shingles or cold sores), and a lowered white blood cell count.
For more details about this treatment, visit:
FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis – MarketWatch
Mavenclad (cladribine) – MS Trust
We never share your personal information with anyone.Continue with Facebook Sign up with your email